Federal - HR 449

A bill to require the Surgeon General of the Public Health Service to submit to Congress a report on the effects on public health of the increased rate of use of synthetic drugs.

Introduced

January 11, 2017

Description

A bill to require the Surgeon General of the Public Health Service to submit to Congress a report on the effects on public health of the increased rate of use of synthetic drugs.

Our Position

Support

Original Sponsor 1

Co-Sponsors 47

Latest Actions See More/Less

  • June 13, 2018 — Received in the Senate and referred to the Senate Health, Education, Labor and Pensions Committee. Congressional Record p. S3904

  • June 12, 2018 — Measure, as amended, passed in the House by voice vote, under suspension of the rules (two-thirds vote required). Congressional Record p. H5031

  • June 12, 2018 — Latta, R-Ohio, motion to suspend the rules and pass the bill, as amended, agreed to by voice vote. Congressional Record p. H5029-H5031

  • June 12, 2018 — Additional cosponsor(s): 1

    Kilmer, (D-Wash.)
  • June 1, 2018 — Additional cosponsor(s): 1

    Posey, (R-Fla.)
  • May 22, 2018 — Additional cosponsor(s): 2

    Bost, (R-Ill.)Walden, (R-Ore.)
  • May 9, 2018 — Full committee consideration and markup held by the House Energy and Commerce Committee.

    May 9, 2018 — Committee Vote: Synthetic Drug Use Report — Vote to Report

    Require the U.S. surgeon general, within three years of the bill's enactment, to submit a comprehensive report to Congress on the public health effects of the rise in synthetic drug use among youth aged 12 to 18 in order to further educate parents and the medical community on the health effects of synthetics. The bill would define a synthetic drug as a drug which is developed and manufactured to avoid control under the Controlled Substances Act.

    Require the U.S. surgeon general, within three years of the bill's enactment, to submit a comprehensive report to Congress on the public health effects of the rise in synthetic drug use among youth aged 12 to 18 in order to further educate parents and the medical community on the health effects of synthetics. The bill would define a synthetic drug as a drug which is developed and manufactured to avoid control under the Controlled Substances Act.

    Ordered reported favorably to the full House by voice vote.
  • May 9, 2018 — Additional cosponsor(s): 1

    Blackburn, M. (R-Tenn.)
  • April 25, 2018 — Subcommittee consideration and markup held by the House Energy and Commerce Committee, Subcommittee on Health.

    April 25, 2018 — Subcommittee Vote: Synthetic Drug Use Report — Psychoactive Substance
    G. Green, D-Texas —

    Amendment that would insert a new section defining the term "new psychoactive substance" as a controlled substance analogue.

    Amendment that would insert a new section defining the term "new psychoactive substance" as a controlled substance analogue.

    Adopted by unanimous consent.

    April 25, 2018 — Subcommittee Vote: Synthetic Drug Use Report — Vote to Approve

    Require the U.S. surgeon general, within three years of the bill's enactment, to submit a comprehensive report to Congress on the public health effects of the rise in synthetic drug use among youth aged 12 to 18 in order to further educate parents and the medical community on the health effects of synthetics. The bill would define a synthetic drug as a drug which is developed and manufactured to avoid control under the Controlled Substances Act.

    Require the U.S. surgeon general, within three years of the bill's enactment, to submit a comprehensive report to Congress on the public health effects of the rise in synthetic drug use among youth aged 12 to 18 in order to further educate parents and the medical community on the health effects of synthetics. The bill would define a synthetic drug as a drug which is developed and manufactured to avoid control under the Controlled Substances Act.

    Approved for full committee consideration (as amended) by unanimous consent.
  • Feb. 13, 2018 — Additional cosponsor(s): 1

    Slaughter, (D-N.Y.)
  • Jan. 29, 2018 — Additional cosponsor(s): 1

    Shea-Porter, (D-N.H.)
  • Dec. 19, 2017 — Additional cosponsor(s): 1

    Faso, (R-N.Y.)
  • Oct. 12, 2017 — Additional cosponsor(s): 1

    DeSaulnier, (D-Calif.)
  • Sept. 26, 2017 — Additional cosponsor(s): 1

    Khanna, (D-Calif.)
  • Sept. 6, 2017 — Additional cosponsor(s): 1

    Krishnamoorthi, (D-Ill.)
  • July 28, 2017 — Additional cosponsor(s): 1

    Ruiz, (D-Calif.)
  • July 27, 2017 — Additional cosponsor(s): 1

    Lujan, B.R. (D-N.M.)
  • July 13, 2017 — Additional cosponsor(s): 3

    Cardenas, (D-Calif.)Peters, S. (D-Calif.)Tonko, (D-N.Y.)
  • July 11, 2017 — Additional cosponsor(s): 1

    Engel, (D-N.Y.)
  • July 10, 2017 — Additional cosponsor(s): 2

    Norcross, (D-N.J.)Walberg, (R-Mich.)
  • June 29, 2017 — Additional cosponsor(s): 6

    Clarke, Y. (D-N.Y.)Jenkins, E. (R-W.Va.)Rush, (D-Ill.)
    Fitzpatrick, (R-Pa.)MacArthur, (R-N.J.)Walters, Mimi (R-Calif.)
  • June 27, 2017 — Additional cosponsor(s): 1

    Davis, R. (R-Ill.)
  • June 26, 2017 — Additional cosponsor(s): 1

    Blunt Rochester, (D-Del.)
  • May 2, 2017 — Additional cosponsor(s): 1

    Comstock, (R-Va.)
  • March 29, 2017 — Additional cosponsor(s): 1

    McKinley, (R-W.Va.)
  • March 27, 2017 — Additional cosponsor(s): 2

    Kuster, (D-N.H.)Olson, (R-Texas)
  • March 16, 2017 — Additional cosponsor(s): 1

    Mullin, (R-Okla.)
  • March 6, 2017 — Additional cosponsor(s): 2

    Allen, (R-Ga.)Joyce, (R-Ohio)
  • Feb. 28, 2017 — Additional cosponsor(s): 1

    King, P. (R-N.Y.)
  • Feb. 27, 2017 — Additional cosponsor(s): 2

    Bilirakis, G. (R-Fla.)Rooney, T. (R-Fla.)
  • Feb. 24, 2017 — Additional cosponsor(s): 1

    Thornberry, (R-Texas)
  • Feb. 21, 2017 — Additional cosponsor(s): 2

    Donovan, (R-N.Y.)Stefanik, (R-N.Y.)
  • Feb. 17, 2017 — Additional cosponsor(s): 1

    Cramer, (R-N.D.)
  • Feb. 9, 2017 — Additional cosponsor(s): 1

    Sensenbrenner, (R-Wis.)
  • Jan. 11, 2017 — Original cosponsor(s): 4

    Butterfield, (D-N.C.)Gowdy, (R-S.C.)
    Collins, C. (R-N.Y.)Meehan, (R-Pa.)
  • Jan. 11, 2017 — Read twice and referred to: House Energy and Commerce.Congressional Record p. H390

-->